MARTIN BLACK, M.D.; WILBERT E. SCOTT Jr., M.D.; ROBERT KANTER, M.D.
Ranitidine (Zantac; Glaxo Incorporated, Research Triangle Park, North Carolina) is a newly introduced H2-receptor antagonist approved by the Food and Drug
Administration for short-term oral use in the treatment of duodenal ulcer and for unrestricted use in hypersecretory states such as the Zollinger-Ellison syndrome (1). Although increased serum aminotransferase levels have been found with parenteral administration of the drug (and are mentioned in the manufacturer's package insert) (2), few reports of clinical hepatotoxicity during therapy with the oral preparation have appeared despite widespread use of the drug in Europe, Australia, and Canada (3, 4). We report the occurrence of symptomatic
BLACK M, SCOTT WE, KANTER R. Possible Ranitidine Hepatotoxicity. Ann Intern Med. ;101:208–210. doi: 10.7326/0003-4819-101-2-208
Download citation file:
Published: Ann Intern Med. 1984;101(2):208-210.
Emergency Medicine, Gastroenterology/Hepatology, Liver Disease.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use